|
Hemato-oncology
Treatment pattern of chronic lymphocytic leukemia/small lymphocytic lymphoma in Korea: a multicenter retrospective study (KCSG LY20-06)
Jung Sun Kim, Tae Min Kim, Myoung Joo Kang, Sung Ae Koh, Hyunkyung Park, Seung-Hyun Nam, Jae Joon Han, Gyeong-Won Lee, Young Jin Yuh, Hee Jeong Lee, Jung Hye Choi
Korean J Intern Med. 2023;38(5):747-757. Published online June 26, 2023
Background/Aims: Little attention is paid to chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Korea due to the rarity of the disease. With its rising incidence, we aimed to evaluate recent changes in treatment patterns and survival outcomes of patients with CLL/SLL.
Methods: A t..
|
|
|
The 2020 revision of the guidelines for the management of myeloproliferative neoplasms
Sung-Yong Kim, Sung Hwa Bae, Soo-Mee Bang, Ki-Seong Eom, Junshik Hong, Seongsoo Jang, Chul Won Jung, Hee-Jin Kim, Ho Young Kim, Min Kyoung Kim, Soo-Jeong Kim, Yeung-Chul Mun, Seung-Hyun Nam, Jinny Park, Jong-Ho Won, Chul Won Choi
Korean J Intern Med. 2021;36(1):45-62. Published online December 4, 2020
In 2016, the World Health Organization revised the diagnostic criteria for myeloproliferative neoplasms (MPNs) based on the discovery of disease-driving genetic aberrations and extensive analysis of the clinical characteristics of patients with MPNs. Recent studies have suggested that additional som..
|
|
|
Hemato-oncology
Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial
Ho-Young Yhim, Won-Il Choi, Sung-Hyun Kim, Seung-Hyun Nam, Kyoung Ha Kim, Yeung-Chul Mun, Doyeun Oh, Hun-Gyu Hwang, Keun-Wook Lee, Eun-Kee Song, Yong Shik Kwon, Soo-Mee Bang
Korean J Intern Med. 2019;34(5):1125-1135. Published online May 23, 2018
Background/Aims: Limited data are available regarding the efficacy of rivaroxaban for the treatment of cancer-associated venous thromboembolism (VTE). The aim of this study was to evaluate the effectiveness and safety of rivaroxaban for the treatment of VTE in active cancer patients.
Methods: In th..
|
|
|
Hand-Foot Syndrome with Scleroderma-like Change Induced by the Oral Capecitabine: A Case Report
Sehe-Dong Lee, Hye-Jeong Kim, Seung-Jae Hwang, Yoon-Jung Kim, Seung-Hyun Nam, Bong-Seog Kim
Korean J Intern Med. 2007;22(2):109-112. Published online June 30, 2007
Hand-foot syndrome (HFS) is a well-known adverse event associated with capecitabine, a prodrug of 5-Fluorouracil (5-FU). HFS manifests as acral erythema, with swelling and dysesthesia of the palms and plantar aspects of the feet, which in the absence of dosage reduction or drug cessation, progres..
|
|
|
Capecitabine and Oxaliplatin (XELOX) for the Treatment of Patients with Metastatic Gastric Cancer and Severe Liver Dysfunction
Seung Jae Hwang, Jong Won Park, Sehe Dong Lee, Gyong Jung Kim, Cheol Ho Sin, Seung-Hyun Nam, Bong-Seog Kim
Korean J Intern Med. 2006;21(4):252-255. Published online December 31, 2006
Gastric cancer patients with severe liver dysfunction secondary to hepatic metastases have limited treatment options. Most cytotoxic drugs have a narrow therapeutic index. Although both capecitabine and oxaliplatin have been well tolerated as single agents for patients with severe hepatic dysfunc..
|
|
|
